AKBA Q2 2018 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+71.1% YoY

Gross Profit

-$23M-47.4% margin

Operating Income

-$36M-73.1% margin

Net Income

-$34M-69.8% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

+6.2%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$414M

Total Liabilities

$248M

Stockholders' Equity

$166M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$29M	+71.1%
Gross Profit	-$23M	-$15M	-51.8%
Operating Income	-$36M	-$22M	-61.1%
Net Income	-$34M	-$22M	-58.3%

Revenue Segments

License And Service

$49M100%